Sluggish start for spring homebuying season as home sales fall in March with mortgage rates rising
Traditionally, spring is the housing market's busiest time of the year.
Meta and its competitors have been churning out new AI language models and hoping to persuade customers they've got the best chatbots.
Traditionally, spring is the housing market's busiest time of the year.
A new buzzword is ringing in the halls of Brussels: competitiveness. European Union leaders are busy debating how to boost their industries and compete with the United States, China and Russia.
The settlement caps a yearslong court battle over Google's location tracking.
Tesla posted record deliveries of more than 1.8 million electric vehicles worldwide in 2023, but the value of its shares has eroded quickly this year as EV sales have soften.
The governors said they want to continue to grow manufacturing in their states, but a successful union drive will “stop this growth in its tracks, to the detriment of American workers.”
HOUSTON — A federal court in Texas denies all claims in this trademark infringement fight between the producers of two tequilas, Casa Azul and Clase Azul. Even if the names are similar, the court rules that consumers will not confuse the brands because the blue-and-white, hand-painted bottle of one of them is more widely recognized than its name.
American said it has an industry-leading safety management system.
On Monday, Trump arrived at a New York court for the start of jury selection in his hush-money trial. It's the first trial of any former U.S. president.
Exxon originally asked for over $1.8 billion in tax refunds, but later dropped claims regarding a separate deal in Malaysia.
CHICAGO — A federal court in Illinois dismissed a nationwide class action brought by consumers against Abbott Labs, whose baby formula prices spiked during a 2022 recall of tainted formula. The court says that the formula maker was not “obligated to maintain particular levels of formula production or supply or otherwise ensure stable formula prices,” and that precedent shows drug manufacturers are not statutorily required to continue supplying their medicine.